Abiopharma

🔍 SULLIVAN GODFREY (Director)

Company: Gitlab Inc. (GTLB)

Report Date: 2026-08-21

Detailed Transactions and Holdings:

• Acquired 12,500 shares of Class A Common Stock (Direct)
  Date: 2026-08-21 | Code: C | equity_swap_involved: 0 | shares_owned_after: 154,874.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 12,500 shares of Class B Common Stock (Derivative)
  Date: 2026-08-21 | Code: C | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1

Footnotes:

• F1: Each share of the Issuer's Class B common stock (the "Class B Stock") is convertible into one share of the Issuer's Class A common stock at any time and will convert automatically upon certain transfers and upon the earlier of (i) ten years from the date of the Issuer's initial public offering ("IPO"), (ii) the death or disability of Sytse Sijbrandij, (iii) the first date following the completion of the IPO on which the number of shares of outstanding Class B Stock (including shares of Class B Stock subject to outstanding stock options) is less than 5% of the aggregate number of shares of the Issuer's common stock then outstanding and (iv) the date specified by a vote of the holders of two-thirds of the then outstanding shares of Class B Stock.
• F2: Includes shares of Class A Common Stock that have not yet vested.
• REMARKS: This Form 4 is being filed solely to report the automatic conversion of the Issuer's Class B Common Stock into Class A Common Stock. The conversion occurred automatically pursuant to the Issuer's Charter and did not involve any discretionary action by the reporting person.